Pipeline
Lytix holds an extensive patent estate protecting its proprietary anti-tumor molecules and their application in immunotherapy across major pharmaceutical markets.
Registrational Study
Combination with pembrolizumab
Neoadjuvant resectable melanoma patients
Ruxotemitide (LTX-315)
Registrational Study – Neoadjuvant Melanoma
Ruxotemitide is an oncolytic peptide that has consistently delivered strong tumor activity, excellent tolerability and clear systemic immune engagement in Phase 2 trials. As a monotherapy, ruxotemitide enables rapid tumor destruction, robust immune cell infiltration and complete regression in injected tumors. Ruxotemitide also delivers abscopal effects in distant metastases, demonstrating clear systemic immune activation.
In combination with immune checkpoint inhibitors, ruxotemitide affords disease control in patients who had previously failed immune checkpoint inhibitor therapy, indicating the impact ruxotemitide can have on the current standard of care for many cancers in the neoadjuvant setting.
Monotherapy
Basal cell carcinoma
Ruxotemitide (LTX-315)
Monotherapy – Basal Cell Carcinoma
Verrica Pharmaceuticals has generated impressive Phase 2 data in basal cell carcinoma with ruxotemitide as a monotherapy. They have reported a 51% complete response rate, and clinical responses in 97% of the patients with significant reduction of tumor size.
Additionally, Verrica has demonstrated that ruxotemitide reprograms the tumor microenvironment, with patient biopsies showing significant increases in CD4+, CD8+ T cells, and B-cells, indicating strong recruitment of effector immune populations into the tumor.
NeoLIPA
Investigator-initiated study
Neoadjuvant resectable melanoma patients
Ruxotemitide (LTX-315)
NeoLIPA Study
Ruxotemitide is currently being evaluated in an investigator-initiated Phase 2 study 'NeoLIPA' in patients with resectable melanoma prior to surgery. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDA®).
The objective of this study is to demonstrate that ruxotemitide improves outcomes in these patients and prevents disease recurrence.
Mono-and combination therapy
Solid tumors (deep seated lesions)
LTX-401
Deep-Seated Solid Tumors
LTX-401 is an oncolytic molecule designed for deep-seated tumors.
LTX-401 expands our oncolytic molecule platform into deep-seated tumors through image-guided intratumoral delivery. This opens access to the liver and other internal tumors where intratumoral treatment has historically not been feasible.
LTX-401 has demonstrated strong proof-of-concept in multiple difficult-to-treat cancer models, including curing animals of liver cancer, and is currently in last-stage pre-clinical development.